中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(3): 577-581

Influence of serum heat shock protein 90α on the prognosis of patients with hepatocellular carcinoma after transarterial chemoembolization

DOI: 10.3969/j.issn.1001-5256.2022.03.016
  • 1.

    School of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China

  • 2.

    Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • 3.

    Department of Hepatobiliary Surgery, Chengdu First People's Hospital, Chengdu 610041, China

Research funding:

Scientific Research Project of Sichuan Medical Association (Youth Innovation) (S20062)

More Information
  • Corresponding author: YAO Huihua, yhhdrxp@hotmail.com (ORCID: 0000-0002-7803-8565)
  • Received Date: 2021-08-05
  • Accepted Date: 2021-10-08
  • Published Date: 2022-03-20
    Abstract
  •   Objective  To investigate the influence of preoperative serum heat shock protein 90α (HSP90α) level on the survival time of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE).  Methods  A retrospective analysis was performed for the clinical data of 97 patients with hepatocellular carcinoma who received TACE alone in Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, from January 1, 2019 to June 1, 2020. With the median of serum HSP90α level as the cut-off value, the patients were divided into high-level group with 48 patients (HSP90α > 135 ng/L) and low-level group with 49 patients (HSP90α ≤135 ng/L). The chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to calculate the median survival time, and the log-rank test was used for comparison between groups. The log-rank univariate analysis and multivariate Cox regression analysis were used to explore the influencing factors for the survival time of patients after surgery.  Results  There were significant differences between the high-level group and the low-level group in Child-Pugh class (χ2=19.356, P<0.01), tumor necrosis (χ2=9.964, P=0.002), BCLC staging (χ2=22.356, P<0.01), and ECOG score (χ2=6.644, P<0.05). The high-level group had a significantly shorter median survival time than the low-level group (χ2=15.551, P<0.01). HSP90α level (hazard ratio [HR]=1.690, P<0.05) and BCLC staging (HR=2.373, P<0.05) were independent influencing factors for the survival time of patients with hepatocellular carcinoma after TACE.  Conclusion  Preoperative serum HSP90α level is an independent influencing factor for the survival time of patients with hepatocellular carcinoma after TACE, and it is expected to become one of the potential indicators for evaluating the prognosis of patients with hepatocellular carcinoma treated by TACE.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2]
    SIEGHART W, HUCKE F, PECK-RADOSAVLJEVIC M. Transarterial chemoembolization: Modalities, indication, and patient selection[J]. J Hepatol, 2015, 62(5): 1187-1195. DOI: 10.1016/j.jhep.2015.02.010.
    [3]
    FU Y, XU X, HUANG D, et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver Cancer: An official, large-scale, and multicenter clinical trial[J]. EBioMedicine, 2017, 24: 56-63. DOI: 10.1016/j.ebiom.2017.09.007.
    [4]
    CHEN Y. Expression and clinical significance of HSP90α in hepatocellular carcinoma[D]. Tianjin: Tianjin Medical University, 2019.

    陈影. HSP90α在原发性肝细胞癌中的表达特点及临床意义[D]. 天津: 天津医科大学, 2019.
    [5]
    HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. DOI: 10.1002/hep.29086.
    [6]
    LIN W, WANG H, ZHONG M, et al. Effect and molecular mechanisms of jiedu recipe on hypoxia-induced angiogenesis after transcatheter arterial chemoembolization in hepatocellular carcinoma[J]. Evid Based Complement Alternat Med, 2021, 2021: 6529376. DOI: 10.1155/2021/6529376.
    [7]
    YAN YZ, TANG H, YOU J. Meta-analysis of efficacy of Ganfule combined with TACE in the treat-ment of hepatocellular carcinoma[J]. China Med Herald, 2020, 562(32): 87-91. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202032024.htm

    晏远智, 唐恒, 游晶. 肝复乐联合肝动脉化疗栓塞术治疗肝细胞癌有效性的Meta分析[J]. 中国医药导报, 2020, 562(32): 87-91. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202032024.htm
    [8]
    DING Y, HUANG RG. Survival analysis of radiofrequency ablation combined with hepatic artery chemoembolization in the treatment of early liver cancer in the elderly[J]. Chin J Gerontol, 2021, 41(18): 3953-3955. DOI: 10.3969/j.issn.1005-9202.2021.18.021.

    丁一, 黄汝刚. 射频消融术后联合肝动脉化疗栓塞治疗老年早期肝癌的生存分析[J]. 中国老年学杂志, 2021, 41(18): 3953-3955. DOI: 10.3969/j.issn.1005-9202.2021.18.021.
    [9]
    LIANG D, YANG B. Short-term efficacy of oral low-dose Tegafur chemotherapy after transarterial chemoembolization in primary hepatic carcinoma[J]. J BUON, 2019, 24(1): 171-177. http://www.ncbi.nlm.nih.gov/pubmed/30941967
    [10]
    CHEN MY, JUENGPANICH S, HU JH, et al. Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma[J]. World J Gastroenterol, 2020, 26(10): 1042-1055. DOI: 10.3748/wjg.v26.i10.1042.
    [11]
    LI J, ZHU WL, KANG XX, et al. Prognostic factors and model of primary liver cancer treated with transcatheter arterial chemoembolization combined with radiofrequency ablation[J]. Chin J Oncol, 2017, 39(10): 787-791. DOI: 10.3760/cma.j.issn.0253-3766.2017.10.013.

    李靖, 朱文良, 康鑫鑫, 等. 经肝动脉化疗栓塞联合射频消融治疗原发性肝癌的预后影响因素及预测模型[J]. 中华肿瘤杂志, 2017, 39(10): 787-791. DOI: 10.3760/cma.j.issn.0253-3766.2017.10.013.
    [12]
    ZHAO SJ, YANG ZY, LEI SX, et al. Comparison of prognostic value between Child-Pugh score and albumin-bilirubin grading for patients with BCLC-B stage hepatocellular carcinoma[J/CD]. Chin J Hepat Surg(Electronic Edition), 2021, 10(1): 38-42. DOI: 10.3877/cma.j.issn.2095-3232.2021.01.009.

    赵首捷, 杨振宇, 雷世雄, 等. Child-Pugh评分和ALBI分级对BCLC-B期肝癌生存预后预测价值比较[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(1): 38-42. DOI: 10.3877/cma.j.issn.2095-3232.2021.01.009.
    [13]
    YOO YG, YEO MG, KIM DK, et al. Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1alpha[J]. J Biol Chem, 2004, 279(51): 53365-53373. DOI: 10.1074/jbc.M408554200.
    [14]
    SONG X, WANG X, ZHUO W, et al. The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis[J]. J Biol Chem, 2010, 285(51): 40039-40049. DOI: 10.1074/jbc.M110.181941.
    [15]
    WANG X, SONG X, ZHUO W, et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy[J]. Proc Natl Acad Sci U S A, 2009, 106(50): 21288-21293. DOI: 10.1073/pnas.0908151106.
    [16]
    ZOU M, BHATIA A, DONG H, et al. Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression[J]. Oncogene, 2017, 36(15): 2160-2171. DOI: 10.1038/onc.2016.375.
    [17]
    WEI W, LIU M, NING S, et al. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma[J]. BMC Cancer, 2020, 20(1): 6. DOI: 10.1186/s12885-019-6489-0.
    [18]
    TANG Y, LI K, CAI Z, et al. HSP90α combined with AFP and TK1 improved the diagnostic value for hepatocellular carcinoma[J]. Biomark Med, 2020, 14(10): 869-878. DOI: 10.2217/bmm-2019-0484.
    [19]
    TAN LL, BAI WY. The Phosphatidylinositol 3-kinase/AKt pathway in hepatocelluar carcinoma[J]. Int J Dig Dis, 2008, 28(2): 120-122. DOI: 10.3969/j.issn.1673-534X.2008.02.011.

    谭莉莉, 白文元. PI3K/AKt信号通路与肝细胞癌[J]. 国际消化病杂志, 2008, 28(2): 120-122. DOI: 10.3969/j.issn.1673-534X.2008.02.011.
    [20]
    WANG N, CHEN S, ZHANG B, et al. 8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells[J]. Sci Rep, 2018, 8(1): 309. DOI: 10.1038/s41598-017-18701-3.
    [21]
    CHUNG TW, LEE YC, KIM CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: Involvement of invasive potential[J]. FASEB J, 2004, 18(10): 1123-1125. DOI: 10.1096/fj.03-1429fje.
    [22]
    SIDERA K, GAITANOU M, STELLAS D, et al. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2[J]. J Biol Chem, 2008, 283(4): 2031-2041. DOI: 10.1074/jbc.M701803200.
    [23]
    LI H, LI WH, ZHANG ZX, et al. Expression of heat shock protein 90α in HBV-related hepatocellular carcinoma[J]. Academic J Guangzhou Med Univ, 2014, 42(6): 21-24. DOI: 10.3969/j.issn.1008-1836.2014.06.008.

    李慧, 李卫华, 张志翔, 等. 热休克蛋白90α在HBV相关性肝细胞癌中表达的意义[J]. 广州医科大学学报, 2014, 42(6): 21-24. DOI: 10.3969/j.issn.1008-1836.2014.06.008.
    [24]
    LUO XH, GUI PG, DU YH. Evaluation of prognostic value of HSP90α combined with tumor marker level in prognosis evaluation of patients with hepatocellular carcinoma[J]. Pract J Cancer, 2019, 34(9): 1405-1408. DOI: 10.3969/j.issn.1001-5930.2019.09.004.

    罗小怀, 桂普国, 杜一鸿. HSP90α联合肿瘤标志物水平检测对肝癌患者预后的评估价值[J]. 实用癌症杂志, 2019, 34(9): 1405-1408. DOI: 10.3969/j.issn.1001-5930.2019.09.004.
    [25]
    ZHANG B, CHEN RH, YANG W, et al. Application of serum HSP90α and PIVKA-Ⅱ levels in prognosis of patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 24(4): 548-551. DOI: 10.3969/j.issn.1672-5069.2021.04.024.

    张兵, 陈瑞红, 杨威, 等. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(4): 548-551. DOI: 10.3969/j.issn.1672-5069.2021.04.024.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (395) PDF downloads(53) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return